AMBS if you are interested in learning some more from this spectacular news here is a snippet . Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in neurology and orphan indications, today announced positive data for Eltoprazine in a Phase 2 clinical trial of elderly patients with Alzheimer's dementia who are aggressive. Eltoprazine is a selective 5HT1a/1b partial agonist in development by Amarantus for the treatment Parkinson's disease levodopa-induced dyskinesia, and is now poised for further clinical development as a symptomatic treatment in adult ADHD and Alzheimer's aggression.